glp-1 news 2025 october 16 Perspectives from employers on the costs and issues associated with covering agonists for weight loss McKee's proposed FY2027 budget drops

10.1111/jpn.12959 J

It is a metabolic strategy with measurable outcomes

N., & Liberati, D

FSA/HSA Friendly : They highlight potential reimbursement eligibility for their weight loss treatments

Similar to other well-known amphetamine-type stimulants, chronic use of synthetic cathinone compounds can significantly impact the central nervous system, leading to acute psychosis, hypomania, paranoid ideation, and delusions (Pantelis et al., 1989

If you do, the next step is a conversation with a licensed prescriber ideally one familiar with obesity medicine who can evaluate your full medical history, discuss benefits and risks, and determine whether therapy is appropriate and how insurance coverage looks for your specific plan